¿Ester Neurosciences Ltd., of Tel Aviv, Israel, said its orally active antisense molecule, AS/3, could be the first antisense drug taken to the clinic for myasthenia gravis. That followed demonstration of oral activity in myasthenic animals at extremely low doses. "We expect a clean side-effect profile of AS/3 due to the unique chemical protection of AS/3, which allows for low dosing and high efficacy, and because the blockade of AChE activity is achieved at the pre-expression level," said Talma Brenner, head of the Laboratory of Neuroimmunology in the department of neurology at Hadassah Medical Center in Jerusalem.

No Comments